{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T17:10:49Z","timestamp":1784740249365,"version":"3.55.0"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Merck Sharp & Dohme LLC"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,12]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>Recurrent isocitrate dehydrogenase (IDH) wild-type glioblastoma has no established standard-of-care treatment. Preclinical models have demonstrated that hypoxia-inducible factor-2 alpha (HIF-2\u03b1) contributes to stabilizing the hypoxic environment in glioblastoma. It was thus hypothesized that the first-in-class HIF-2\u03b1 inhibitor, belzutifan, may improve outcomes in patients with recurrent IDH wild-type glioblastoma. The glioblastoma cohort of the phase 1 LITESPARK-001 trial enrolled participants who had received radiotherapy and temozolomide. Although targeting HIF-2\u03b1 may have a role in advancing treatment options for patients with glioblastoma, single-agent belzutifan did not have antitumor activity in this cohort.<\/jats:p>","DOI":"10.1093\/noajnl\/vdaf242","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T13:12:44Z","timestamp":1763557964000},"source":"Crossref","is-referenced-by-count":3,"title":["Phase 1 LITESPARK-001 study of belzutifan in participants with advanced solid tumors: Results of the glioblastoma expansion cohort"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6651-5267","authenticated-orcid":false,"given":"Roy E","family":"Strowd","sequence":"first","affiliation":[{"name":"Department of Neurology, Wake Forest University School of Medicine , Winston-Salem (R.S.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macarena","family":"de la Fuente","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center and Department of Neurology, University of Miami , Miami (M.F.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd M","family":"Bauer","sequence":"additional","affiliation":[{"name":"Greco-Hainsworth Centers for Research\/Tennessee Oncology, PLLC , Nashville (T.B.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyriakos P","family":"Papadopoulos","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology, START San Antonio , San Antonio (K.P.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Chen","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc , Rahway (K.C., R.P., Y.L.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo F","family":"Perini","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc , Rahway (K.C., R.P., Y.L.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfang","family":"Liu","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc , Rahway (K.C., R.P., Y.L.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F","family":"McDermott","sequence":"additional","affiliation":[{"name":"Internal Medicine-Medical Oncology, Beth Israel Deaconess Medical Center , Boston (D.M.)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"2026042813562700700_vdaf242-B1","doi-asserted-by":"crossref","first-page":"665","DOI":"10.7150\/thno.41692","article-title":"Glioma stem cells and their roles within the hypoxic tumor microenvironment","volume":"11","author":"Boyd","year":"2021","journal-title":"Theranostics"},{"key":"2026042813562700700_vdaf242-B2","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14051176","article-title":"Current understanding of hypoxia in glioblastoma multiforme and its response to immunotherapy","volume":"14","author":"Park","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026042813562700700_vdaf242-B3","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.4161\/cc.8.20.9701","article-title":"The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype","volume":"8","author":"Heddleston","year":"2009","journal-title":"Cell Cycle"},{"key":"2026042813562700700_vdaf242-B4","doi-asserted-by":"crossref","first-page":"15195","DOI":"10.1038\/s41598-020-72290-2","article-title":"Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor","volume":"10","author":"Renfrow","year":"2020","journal-title":"Sci Rep"},{"key":"2026042813562700700_vdaf242-B5","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von Hippel-Lindau disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N Engl J Med"},{"key":"2026042813562700700_vdaf242-B6","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJMoa2313906","article-title":"Belzutifan versus everolimus for advanced renal-cell carcinoma","volume":"391","author":"Choueiri","year":"2024","journal-title":"N Engl J Med"},{"key":"2026042813562700700_vdaf242-B7","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41591-021-01324-7","article-title":"Inhibition of hypoxia-inducible factor-2\u03b1 in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis","volume":"27","author":"Choueiri","year":"2021","journal-title":"Nat Med"},{"key":"2026042813562700700_vdaf242-B8","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1158\/1078-0432.CCR-20-2500","article-title":"Randomized phase II and biomarker study of pembrolizumab plus bevacizumab versus pembrolizumab alone for patients with recurrent glioblastoma","volume":"27","author":"Nayak","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026042813562700700_vdaf242-B9","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the checkmate 143 phase 3 randomized clinical trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026042813562700700_vdaf242-B10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00018-025-05642-8","article-title":"Targeting HIF-2\u03b1 in glioblastoma reshapes the immune infiltrate and enhances response to immune checkpoint blockade","volume":"82","author":"Espinoza","year":"2025","journal-title":"Cell Mol Life Sci"}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdaf242\/65415583\/vdaf242.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/8\/1\/vdaf242\/65415583\/vdaf242.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/8\/1\/vdaf242\/65415583\/vdaf242.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T17:56:36Z","timestamp":1777398996000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdaf242\/8332232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,12]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdaf242","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,11,20]]},"article-number":"vdaf242"}}